Under the terms of the agreement, Ortho-McNeil Pharmaceutical will license several lead series of compounds identified by Amphora that are focused on a widely recognized inflammation target for
Rotarix is an oral, two-dose, live attenuated vaccine against rotavirus disease in infants that was licensed in 1997 by Avant Immunotherapeutics to GSK for worldwide commercialization. Rotavirus infection
The first, LX-1521, is a small molecule compound to be developed as a potential cancer treatment. The second, LX-5431, is a protein to be developed as a potential
In the phase IIa trial evaluating Idenix’ lead drug candidate valopicitabine, patients are randomized to one of two treatment arms, valopicitabine (NM283) monotherapy, or valopicitabine (NM283) plus pegylated
CCR5 mAb (CCR5mAb004) is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5. The CCR5 receptor is known to be a key facilitator
“Through our investment in antisense we have advanced the technology to a point where we and our partners now have extensive clinical and pre-clinical development pipelines that are
Zymed produces pathology products, cancer and cell biology reagents and biomarkers, and general immunochemical reagents for the life science research and clinical diagnostics markets. Its antibody collection is
The proposed label expansion for Aceon (perindopril erbumine,)an angiotensin converting enzyme (ACE) inhibitor with tissue activity approved in the US for the treatment of patients with essential hypertension,
SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA-binding protein transcription factor (ZFP TF), designed to upregulate the vascular endothelial growth factor A
The collaborators published their initial findings in April 2004 in a New England Journal of Medicine article. While the previous study was based on samples from patients receiving
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.